Oxbryta (voxelotor), an oral medication approved to treat sickle cell disease (SCD), prevented children’s red blood cells from…
Articles by Margarida Maia, PhD
While children with sickle cell anemia — the most common form of sickle cell disease — are vulnerable to…
Nearly 1 in 3 children and teens with sickle cell disease (SCD) reports persistent or chronic pain, according to…
A biomedical engineer at Kennesaw State University has been given a $426,000 grant to build a low-cost device helping to…
The first patient has been dosed in BEACON, a Phase 1/2 clinical trial of a transplant-based gene-editing stem cell therapy…
Saudi Arabia’s regulatory authorities have approved Casgevy (exagamglogene autotemcel), a one-time gene-editing therapy, to treat sickle cell disease…
A clinical project designed to test whether masitinib, AB Science’s experimental oral therapy for sickle cell disease (SCD), can…
Children and young adults with kidney failure due to sickle cell disease (SCD) wait nearly two times longer for…
More than 1 in 3 children and adolescents with sickle cell disease (SCD) develop retinopathy, or damage to the…
For nearly half of people with sickle cell disease who took part in the Phase 2 part of a…